Ototoxicity after platinum‑based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy

Hojan‑Jezierska,Dorota; Chomiak,Anna; Czopor,Agata; Matthews‑Kozanecka,Maja; Majewska,Anna; Urbaniak‑Olejnik,Marta; Matthews‑Brzozowska,Teresa

doi:10.3892/ol.2020.11447

Ototoxicity after platinum‑based chemotherapy in the treatment of melanotic neuroectodermal tumour of infancy

Authors:
- Dorota Hojan‑Jezierska
- Anna Chomiak
- Agata Czopor
- Maja Matthews‑Kozanecka
- Anna Majewska
- Marta Urbaniak‑Olejnik
- Teresa Matthews‑Brzozowska
View Affiliations

Affiliations: Department of Hearing Healthcare Profession, Chair of Biophysics, University of Medical Sciences, 60‑780 Poznań, Poland, Students Research Group of Department of Clinic of Maxillofacial Orthopaedics and Orthodontics, University of Medical Sciences, 60‑780 Poznań, Poland, Department of Social Sciences, University of Medical Sciences, 60‑780 Poznań, Poland, Department of Maxillofacial Orthopaedics and Orthodontics, University of Medical Sciences, 60‑780 Poznań, Poland
Published online on: March 5, 2020 https://doi.org/10.3892/ol.2020.11447
Pages: 3411-3416
Copyright: © Hojan‑Jezierska et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Melanotic neuroectodermal tumor of infancy (MNTI) is a rare infantile tumor that originates from mesenchymal‑neuroectodermal cells, the treatment of which uses platinum derivatives that can affect hearing loss. The present study evaluated the long‑term effects of ototoxicity following chemotherapy with cisplatin, vincristine, cyclophosphamide, teniposide and adriamycin in a 10‑year‑old patient after surgical removal of a MNTI tumor at the age of 8 months. Audiometric tests (high‑frequency tonal audiometry, speech audiometry, speech acoustics, tympanometry and absorbance measurements) were performed during a 10‑year follow‑up after receiving chemotherapy. Hearing disorders in the high‑frequency range (6,000 to 16,000 Hz range) were demonstrated for both ears, indicating that these may be the long‑term effects of chemotherapy with use of platinum compounds during the treatment of infants.

View Figures

View References

1	Chaudhary S, Manuja N, Ravishankar CT, Sinha A, Vijayran M and Singh M: Oral melanotic neuroectodermal tumor of infancy. J Indian Soc Pedod Prev Dent. 32:71–73. 2014. View Article : Google Scholar : PubMed/NCBI
2	Andrade NN, Mathai PC, Sahu V, Aggarwal N and Andrade T: Melanotic neuroectodermal tumour of infancy-A rare entity. J Oral Biol Craniofac Res. 6:237–240. 2016. View Article : Google Scholar : PubMed/NCBI
3	Neven J, Hulsbergen-van der Kaa C, Groot-Loonen J, de Wilde PC and Merkx MA: Rucurrent melanotic neuroectodermal tumor of infancy: A proposal for treatment protocol with surgery and adjuvant chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 106:493–496. 2008. View Article : Google Scholar : PubMed/NCBI
4	Ubale P, Baldwa N and Gujjar P: Anaesthetic management of a neuroectodermal tumor of infancy: A rare case report. Anaesth Essays Res. 11:251–253. 2017. View Article : Google Scholar
5	Łyskawa W: Chemiotherapy in the neoplasmatic diseases treatment and its neurotoxicity. Anestezjol i Ratow. 3:80–87. 2009.
6	Karasawa T and Steyger PS: An integrated view of cisplatin-induced nephrotoxicity and ototoxicity. Toxicol Lett. 237:219–227. 2015. View Article : Google Scholar : PubMed/NCBI
7	Işık A, Grassi A and Soran A: Positive axilla in breast cancer; clinical practice in 2018. Eur J Breast Health. 14:134–135. 2018.PubMed/NCBI
8	Isik A, Karavas E and Firat D: Spontaneous milk fistula from an axillary accessory breast. Breast J. 25:1542019. View Article : Google Scholar : PubMed/NCBI
9	Olgun Y, Aktaş S, Altun Z, Kırkım G, Kızmazoğlu DÇ, Erçetin AP, Demir B, İnce D, Mutafoğlu K, Demirağ B, et al: Analysis of genetic and non genetic risk factors for cisplatin ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol. 90:64–69. 2016. View Article : Google Scholar : PubMed/NCBI
10	Breglio AM, Rusheen AE, Shide ED, Fernandez KA, Spielbauer KK, McLachlin KM, Hall MD, Amable L and Cunningham LL: Cisplatin is retained in the cochlea indefinitely following chemotherapy. Nat Commun. 8:16542017. View Article : Google Scholar : PubMed/NCBI
11	Einarsson EJ, Petersen H, Wiebe T, Fransson PA, Grenner J, Magnusson M and Moëll C: Long term hearing degeneration after platinum-based chemotherapy in childhood. Int J Audiol. 49:765–771. 2010. View Article : Google Scholar : PubMed/NCBI
12	Dean JB, Hayashi SS, Albert CM, King AA, Karzon R and Hayashi RJ: Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens. J Pediatr Hematol Oncol. 30:130–134. 2008. View Article : Google Scholar : PubMed/NCBI
13	Sheth S, Mukherjea D, Rybak LP and Ramkumar V: Mechanisms of cisplatin-induced ototoxicity and otoprotection. Front Cell Neurosci. 11:3382017. View Article : Google Scholar : PubMed/NCBI
14	Clemens E, de Vries AC, Pluijm SF, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, et al: Determinants of ototoxicity in 451 platinum-treated Dutch survivors of childhood cancer: A DCOG late-effects study. Eur J Cancer. 69:77–85. 2016. View Article : Google Scholar : PubMed/NCBI
15	Bertolini P, Lassalle M, Mercier G, Raquin MA, Izzi G, Corradini N and Hartmann O: Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss. J Pediatr Hematol Oncol. 26:649–655. 2004. View Article : Google Scholar
16	Bess FH, Dodd-Murphy J and Parker RA: Children with minimal sensorineural hearing loss: Prevalence, educational performance, and functional status. Ear Hear. 19:339–354. 1998. View Article : Google Scholar
17	Davis JM, Elfenbein J, Schum R and Bentler RA: Effects of mild and moderate hearing impairments on language, educational, and psychosocial behavior of children. J Speech Hear Disord. 51:53–62. 1986. View Article : Google Scholar : PubMed/NCBI
18	Sergi B, Ferraresi A, Troiani D, Paludetti G and Fetoni AR: Cisplatin ototoxicity in the guinea pig: Vestibular and cochlear damage. Hear Res. 182:56–64. 2003. View Article : Google Scholar : PubMed/NCBI
19	Clemens E, de Vries AC, Am Zehnhoff-Dinnesen A, Tissing WJ, Loonen JJ, Pluijm SF, van Dulmen-den Broeder E, Bresters D, Versluys B, Kremer LC, et al: Hearing loss after platinum treatment is irreversible in noncranial irradiated childhood cancer survivors. Pediatr Hematol Oncol. 34:120–129. 2017. View Article : Google Scholar : PubMed/NCBI
20	Lin CP, Liu JD, Chow JM, Liu CR and Liu HE: Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells. Anticancer Drugs. 18:161–117. 2007. View Article : Google Scholar : PubMed/NCBI
21	Fetoni AR, Ruggiero A, Lucidi D, De Corso E, Sergi B, Conti G and Paludetti G: Audiological monitoring in children treated with platinum chemotherapy. Audiol Neurootol. 21:203–211. 2016. View Article : Google Scholar : PubMed/NCBI
22	Waissbluth S, Chuang A, Del Valle Á and Cordova M: Long term platinum-induced ototoxicity in pediatric patients. Int J Pediatr Otorhinolaryngol. 107:75–79. 2018. View Article : Google Scholar : PubMed/NCBI
23	Kushner BH, Budnick A, Kramer K, Modak S and Cheung NK: Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 107:417–422. 2006. View Article : Google Scholar : PubMed/NCBI
24	Liberman PH, Goffi-Gomez MV, Schultz C, Novaes PE and Lopes LF: Audiological profile of patients treated for childhood cancer. Braz J Otorhinolaryngol. 82:623–629. 2016. View Article : Google Scholar : PubMed/NCBI